scroll down


scroll down

Our multifunctional biologics target specific cells, improving treatment efficacy while minimizing side effects.   

  • In the past, the focus was on specific proteins for signaling within cells. 
  • Our approach takes a holistic view, analyzing the functionally relevant cell surface proteome to design our multifunctional biologics, named Tentacles. 
  • Our strategy involves binding signaling receptors and other cell markers, allowing us to leverage combinatorial avidity for precise targeting. 

Despite the vast potential of multi-specifics, their development has been constrained by numerous challenges, including issues related to developability, complex biology, and desired pharmacology.

The Tentacle™ signifies our advanced approach for precisely targeting powerful biology for improved therapeutic outcomes.

The octopus is a highly intelligent creature. Just like an octopus’s versatile tentacles, our therapies are precise, multi-functional, and intelligently designed to target specific cells for better health outcomes. 

Defining Key Features of Cells Involved in Disease

Understanding cell surface proteomes in healthy and diseased cells. 

Discovering Tentacle Components

Encompassing the human immune system within a mammalian display platform for fully human binder discovery. 

Tailoring Specific Agonists

Employing a function-first platform to create and screen millions of Tentacles. 

A Modular, Intelligent Platform for Discovering Developable Biologics

Not only are Tentacleshighly-effective multifunctional biologics, the Tentacles platform is modular, so it can be used to create biologics that treat a range of diseases. The classes of molecules or pathways currently in the pipeline include conditional immune cell agonists and specific cellular re-programmers to address autoimmune disorders and cancer.

Computational Stabilization of All Functional VH Domains in the Human Genome

Protein Expression Level
Protein Thermal Stability

* Did not express

Tentacle Agonist with >1,000x Conditionality

  • AbbVie and Tentarix Announce Collaboration to Develop Conditionally-Active, Multi-Specific Biologics for Oncology and Immunology Read the full story

  • Tentarix Biotherapeutics Completes Series B Financing Bringing Total Equity and Upfront Deal Consideration to $132 Million Read the full story

  • Gilead and Tentarix to Discover and Develop Novel Therapies to Address Unmet Medical Needs Across Cancer and Inflammation Read the full story

Tentarix Biotherapeutics is led by an executive team with years—often decades—of expertise in the field of multifunctional drug discovery. We are looking to hire highly-qualified, motivated individuals who, like us, want to revolutionize the disease therapy landscape.

Tentarix team members are creative, self-driven, and team-oriented. They’re also effective communicators determined to contribute to the company’s success. 

We know that our employees are our most valuable asset, so we provide desirable benefits and compensation accordingly. And we offer a modern, flexible work culture with the tools to ensure that we succeed not only as individuals but as a collective. 

Tentarix is committed to equal opportunity in the terms and conditions of employment for all employees and job applicants without regard to race, color, religion, sex, sexual orientation, age, gender identity or gender expression, national origin, disability or veteran status.

Tentarix Biotherapeutics, Inc. also complies with all applicable national, state and local laws governing nondiscrimination in employment as well as work authorization and employment eligibility verification requirements of the Immigration and Nationality Act and IRCA. We are an E-Verify employer.